The election is over, cabinet re-shuffling has begun, and hopefully you properly prepared and stored your food and avoided poisoning family and friends over the Thanksgiving holiday. As you can imagine, food preparation at a food and drug law firm is a very serious business. We regularly swap favorite turkey brining and stuffing recipes and […]
Compounding, Again Read More »
The election is over and the current Administration will stay in the White House. Food labeling may not have been among the top issues on the minds of American voters. But the election results will have an impact on food manufacturers, retailers, and restaurant operators who are concerned about the prospect of new FDA regulations,
Food Labeling Politics – What the Election Results May Mean for Your Company Read More »
As the impact of the deadly meningitis outbreak grows, questions about FDA’s authority to regulate pharmacy compounding have arisen. New England Compounding Center Inc.’s (NECC) tainted, injectable steroid, methylprednisolone acetate, is now linked to 461 infections, including 32 deaths. In testimony this week before the House Energy and Commerce Subcommittee on Oversight and Investigations, FDA
Can FDA Regulate Compounding? FDA Doesn’t Think So. . . But It Kind of Tried To Read More »
By Mark L. Itzkoff Over the past few months, articles have been published claiming possible links between bisphenol A (BPA) and a variety of human health problems including obesity, thyroid changes, and male infertility. Many of the recent stories leave consumers misinformed about possible exposure to BPA and implicate products that do not contain BPA. For example, NBC News
BPA: The Press Rounds Up the Usual Suspects and Gets it Wrong Read More »
Among the casualties on election day this year was California Prop 37, defeated by a vote of 53% to 47%. Proposition 37, the California Right to Know Genetically Engineered Food Act, was a ballot initiative that would have required special labeling of foods that have been genetically engineered or contain genetically engineered ingredients. According to
California Prop 37 Fails to Pass Read More »
It’s been a weird week. The “Frankenstorm” also known as Sandy blew through Washington, closing everything from the stalwart federal government to the Metro system. OFW Law weathered the storm pretty well, though the view outside my window of the muddy, debris-filled Potomac is an ever-present reminder that our problems pale in comparison to those
By Kathryn E. Balmford Back in January, Jeff Shuren, M.D., the Director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration (FDA), made headlines when comparing the European Union’s (EU) regulation of medical devices to FDA’s. When asked by a reporter whether proposed changes to FDA’s 510(k) premarket clearance system
There are some spectacles we geeks in the food and drug bar follow as avidly as any mini-series. The epic, two-year battle between POM Wonderful (producer of pomegranate products) and the Federal Trade Commission (FTC) is almost as addictive as HBO’s “Game of Thrones” – only without all the beheadings. Though POM Wonderful extols the health
POM Wonderful vs. FTC: The Epic War Continues Read More »
The number of class action lawsuits targeting food labeling claims has risen dramatically over the past few years. These are cases alleging that a food product’s labeling (and/or advertising) violates state consumer protection laws. As a result, when a food company now considers whether to include an aggressive claim in commercial marketing, it should consider
By Casper E. Uldriks The verification of design specifications and functional validation of software is predicated on its intended use with a particular device or as a “stand alone” device. The U.S. Food and Drug Administration (FDA) and the industry have understood and used software validation principles ever since the enactment of the Medical Device
The FDA Regulatory Challenges of Software Interoperability and Part 806 Read More »
Medical device companies often find themselves in a bind if the U.S. Food and Drug Administration (FDA) scrutinizes their decisions that product changes did not trigger the regulatory requirement for a new 510(k) submission for the changed device. They often use a thought process that is unacceptable to FDA. In other cases, they do not
